Cardiology

Your daily dose of clinical news you may have missed.

Oral estrogen hormone therapy was more likely to result in incident hypertension than transdermal or vaginal formulations in this large prospective population-based study.

Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.

Increased levels of lipoprotein(a) significantly and independently predicted recurrent CHD events in adults aged 60 years and older, report study authors.

FDA fast tracks triple-threat antithrombotic, dangers of faux semaglutide online, a guide to neurologic sequelae of COVID-19, plus 2 more reviews of note.

Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.

Your daily dose of clinical news you may have missed.

In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.

Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.

The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.

After an acute myocardial infarction, adults with diabetes were over 50% more likely to die after 1 year than those without diabetes, a new study shows.

Your daily dose of clinical news you may have missed.

Symptoms of long COVID were apparent by the summer of 2020, said physiatrist Dr Leslie Rydberg, coauthor of new consensus guidelines on management of neurologic sequelae.

As indicated by levels of 2 common biomarkers of cardiac injury, 33.4% of US adults with T2D showed evidence of undetected CVD vs only 16.1% of those without T2D.

The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.

At the 2023 American Thoracic Society International Conference a symposium focused on common comorbidities seen with COPD, their management, and research needs.

Bayer's investigational FXIa inhibitor is currently being studied in a large-scale phase 3 development program expected to enroll more than 27 000 participants.

Efficacy of the daily pill met the standard now established by the once-weekly injection of 15% loss of baseline bodyweight in adults with overweight or obesity, says Novo Nordisk.

Your daily dose of clinical news you may have missed.

Statin therapy initiated within 1 year of diagnosis of atrial fibrillation reduced the risk of ischemic stroke or systemic embolism by nearly 20%.

Findings also showed that between 1990 and 2019, the global number of ischemic stroke deaths rose from 2 million to 3 million.

“Patients with COPD who have AMI are less aggressively treated than those without COPD," leading to higher in-hospital mortality and long-term mortality,” wrote authors.

The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with HFmrEF or HFpEF.

Women's Health Week (May 14-20, 2023) is an ideal opportunity to review the top research, policy shifts, and potential drug approvals that affect your patient panel.

Your daily dose of clinical news you may have missed.